- Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection
[作者:Mackiewicz, A; Mackiewicz, J; Wysocki, PJ; Wiznerowicz, M; Kapcinska, M; Laciak, M; Rose-John, S; Izycki, D; Burzykowski, T; Karczewska-Dzionk, A,期刊:Expert opinion on investigational drugs, 页码:773-783 , 文章类型: Article,,卷期:2012年21-6]
- Objective: Two single arm, Phase II trials (3 and 5) were undertaken to determine the efficacy and toxicity of an adjuvant treatment using Hyper-IL-6 gene-modified whole-cell allogeneic melanoma vaccine in patients with ...
- Regorafenib for cancer
[作者:Strumberg, D; Schultheis, B,期刊:Expert opinion on investigational drugs, 页码:879-889 , 文章类型: Editorial Material,,卷期:2012年21-6]
- Introduction: Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-beta, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase.Areas covered: This review covers t...
|